Page 20 - Ace2 News Today

February 15, 2021 -- Researchers have identified interactions between short viral proteins and receptors that facilitate the entry of the SARS-CoV-2 virus into a host. This evidence of molecular links, published in Science Signaling on February 12, may help scientists identify drugs that are highly effective at blocking the virus. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a receptor to attach to host cells. ACE2 is a single-pass type I membrane protein with a short cytosoli...

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

Scientists from Germany have determined the efficacy of currently used therapeutics in treating newer variants of SARS-CoV-2, including the UK, South Africa, and Brazil variants. Their findings reveal that both B.1.351 and B.1.1.248 variants are able to escape humoral immune responses induced by therapeutic antibodies, vaccinations, or natural SARS-CoV-2 infection.

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2 Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). Tetanus toxoid (TT) is a chemically inactivated version of the tetanus toxin produced by the bacteria Clostridium tetani. This ...

A new study by researchers at the University of Connecticut Health Center, USA, reports the crucial nature of the pathogen pattern recognition receptor (PRRs), especially the two RLRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), in triggering host cell immune responses within the cell. The RLRs are viral RNA sensors.

A team of scientists from the United States has recently conducted a study using pericyte-like cell-containing brain cortical organoids as an experimental model to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the central nervous system.

Researchers in the U.S. have demonstrated how dominant energetic landscape mappings or glue points, along with sequence alignment information can potentially identify key residue mutations and spike protein deletions tied with emerging variants.

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization. The SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that has now claimed the lives of more than 2.35 million people. The substrain of th...

Both mRNA vaccines protect against emerging variants of SARS-CoV-2 Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants. The SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a significant threat to global public health ...

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).